DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new indepe

California State Teachers Retirement System increased its stake in Alkermes plc (NASDAQ: ALKS) by 5,

Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and s

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting ap

Alkermes (NASDAQ: ALKS - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are b

The executive sold 7,576 shares. The transaction resulted in a 7% reduction in the insider's direct

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Shares of Alkermes plc (NASDAQ: ALKS - Get Free Report) passed above its 200-day moving average duri

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from th

Bank of America Corp DE decreased its stake in shares of Alkermes plc (NASDAQ: ALKS) by 9.2% in the

Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel

Glenmede Trust Co. NA trimmed its position in shares of Alkermes plc (NASDAQ: ALKS) by 8.4% during t

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the pric

Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price

Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz add

Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and rais

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the q

Alkermes NASDAQ: ALKS reported second-quarter 2026 revenue of $496 million, supported by growth acro

Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate

Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 bil

Alkermes (NASDAQ:ALKS) reported quarterly sales of $496.009 million which beat the analyst consensus

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarte

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings bea

Stifel analyst Paul Matteis reiterates Alkermes (NASDAQ:ALKS) with a Buy and raises the price tar

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast present

Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target

Alkermes reports positive long-term data for alixorexton, showing sustained wakefulness and symptom

Alkermes plc (NASDAQ:ALKS) today announced results from a planned interim analysis of the ongoing lo

On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal&#3

Mizuho analyst Uy Ear maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price tar

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t

Company seeks to advance national expansion through innovative financing model; Founder personally i

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

Jim Cramer recommended selling Super Micro Computer Inc. and doesn't recommend Alkermes plc. Hun

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys